key: cord-0069705-8fkwh343
authors: nan
title: Acknowledgement to Referees
date: 2021-11-11
journal: Clin Drug Investig
DOI: 10.1007/s40261-021-01099-2
sha: 3d3585b82ae489d1d842feb92426b5bca400a026
doc_id: 69705
cord_uid: 8fkwh343

nan

The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.

I would like to start by thanking the authors of the articles published in Clinical Drug Investigation over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.

The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for Clinical Drug Investigation in the last 12 months: 

The cost-effectiveness of a COVID-19 vaccine in a Danish context

Acetylsalicylic acid compared with enoxaparin for the prevention of thrombosis and mechanical ventilation in COVID-19 patients: a retrospective cohort study

Can mRNA vaccines turn the tables during the COVID-19 pandemic? Current status and challenges

Observational study of chlorpromazine in hospitalized patients with COVID-19

Could tocilizumab be an attractive therapeutic option for elderly patients with severe COVID-19? A case report

Proton pump inhibitors are risk factors for viral infections: even for COVID-19?

Azithromycin for COVID-19: more than just an antimicrobial?

An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19)

Rational use of tocilizumab in the treatment of novel coronavirus pneumonia

Sustainable Development Goals (SDG) Programme' is aiming to connect researchers who are tackling the world's toughest challenges with practitioners in policy and business, while the 'Women in Science' initiative aims to help empower more women scientists to achieve scientific excellence. Finally, I am delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet and flights) and earlier this year signed The Climate Pledge

Returning to Clinical Drug Investigation, the editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles over the coming year